{
    "eid": "2-s2.0-85046786100",
    "title": "Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1)",
    "cover-date": "2018-07-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Immunology and Allergy",
            "@code": "2723",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Immunology",
            "@code": "2403",
            "@abbrev": "IMMU"
        }
    ],
    "keywords": [],
    "authors": [
        "Kornvalee Meesilpavikkai",
        "Willem A. Dik",
        "Benjamin Schrijver",
        "Nicole M.A. Nagtzaam",
        "Sandra J. Posthumus-van Sluijs",
        "P. Martin van Hagen",
        "Virgil A.S.H. Dalm"
    ],
    "citedby-count": 28,
    "ref-count": 12,
    "ref-list": [
        "Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype",
        "PD-L1 up-regulation restrains Th17 cell differentiation in STAT3 loss- and STAT1 gain-of-function patients",
        "Gain-of-function STAT1 mutations are associated with PD-L1 overexpression and a defect in B-cell survival",
        "A novel heterozygous mutation in the STAT1 SH2 domain causes chronic mucocutaneous candidiasis, atypically diverse infections, autoimmunity, and impaired cytokine regulation",
        "Treatment options for chronic mucocutaneous candidiasis",
        "Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation",
        "Baricitinib: first global approval",
        "The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers",
        "Signal transduction pathways and transcriptional regulation in Th17 cell differentiation",
        "The emerging safety profile of JAK inhibitors in rheumatic disease",
        "PD-1 and its ligands in tolerance and immunity",
        "A novel heterozygous mutation in the STAT1 SH2 domain causes chronic mucocutaneous candidiasis, atypically diverse infections, autoimmunity, and impaired cytokine regulation"
    ],
    "affiliation": [
        {
            "affiliation-city": "Rotterdam",
            "@id": "60032114",
            "affilname": "Erasmus MC",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032114",
            "affiliation-country": "Netherlands"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "University Medical Center Rotterdam",
        "Faculty of Medicine, Chulalongkorn University"
    ]
}